Results 11 to 20 of about 37,805 (220)

Review immune response of targeting CD39 in cancer

Biomarker Research, 2023
The ATP-adenosine pathway has emerged as a promising target for cancer therapy, but challenges remain in achieving effective tumor control. Early research focused on blocking the adenosine generating enzyme CD73 and the adenosine receptors A2AR or A2BR ...
Yao Liu, Zhongliang Li, Xiaoguang Zhao, Jing Xiao, Jiacheng Bi, Xian-Yang Li, Guokai Chen, Ligong Lu   +7 more
doaj   +3 more sources

CD39 Regulation and Functions in T Cells [PDF]

International Journal of Molecular Sciences, 2021
CD39 is an enzyme which is responsible, together with CD73, for a cascade converting adenosine triphosphate into adenosine diphosphate and cyclic adenosine monophosphate, ultimately leading to the release of an immunosuppressive form of adenosine in the tumor microenvironment.
eleonora timperi, Vincenzo Barnaba
openaire   +2 more sources

Thrombo-Inflammation: A Focus on NTPDase1/CD39 [PDF]

Cells, 2021
There is increasing evidence for a link between inflammation and thrombosis. Following tissue injury, vascular endothelium becomes activated, losing its antithrombotic properties whereas inflammatory mediators build up a prothrombotic environment.
Morello, Silvana, Caiazzo, Elisabetta, Turiello, Roberta, Cicala, Carla   +3 more
openaire   +5 more sources

Ability of γδ T cells to modulate the Foxp3 T cell response is dependent on adenosine. [PDF]

, 2018
Whether γδ T cells inhibit or enhance the Foxp3 T cell response depends upon their activation status. The critical enhancing effector in the supernatant is adenosine.
Born, Willi K, Kaplan, Henry J, Liang, Dongchun, O'Brien, Rebecca L, Shao, Hui, Sun, Deming, Woo, Jeong-Im   +6 more
core   +10 more sources

CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes. [PDF]

PLoS ONE, 2018
The ectoenzymes CD39 and CD73 degrade extracellular ATP to adenosine. ATP is released by stressed or damaged cells and provides pro-inflammatory signals to immune cells through P2 receptors.
Friederike Raczkowski, Anne Rissiek, Isabell Ricklefs, Kirsten Heiss, Valéa Schumacher, Kira Wundenberg, Friedrich Haag, Friedrich Koch-Nolte, Eva Tolosa, Hans-Willi Mittrücker   +9 more
doaj   +1 more source

Assessment of CD4⁺ cells subpopulations with the expressing CD39 and CD73 ectonucleotidases in children with psoriasis

Медицинская иммунология, 2022
Purinergic signaling modulates systemic and local inflammatory responses in immune-mediated and autoimmune diseases, including psoriasis. Extracellular ATP is an important factor of purinergic regulation, and its levels are regulated by catalytic effects
D. G. Kuptsova, T. V. Radigina, S. V. Petrichuk, N. N. Murashkin, A. A. Khotko, R. A. Ivanov   +5 more
doaj   +1 more source

Human soluble CD39 displays substrate inhibition in a substrate-specific manner

Scientific Reports, 2023
CD39 (ectonucleoside triphosphate diphosphohydrolase-1; ENTPD1) metabolizes extracellular ATP and ADP to AMP. AMP is subsequently metabolized by CD79 to adenosine. CD39 activity is therefore a key regulator of purinergic signalling in cancer, thrombosis,
Venkat M. K. Vadlamani, Kavinda K. J. Gunasinghe, Xavier W. Chee, Taufiq Rahman, Matthew T. Harper   +4 more
doaj   +1 more source

CD39 and control of cellular immune responses [PDF]

Purinergic Signalling, 2007
CD39 is the cell surface-located prototypic member of the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) family. Biological actions of CD39 are a consequence (at least in part) of the regulated phosphohydrolytic activity on extracellular nucleotides.
Dwyer, Karen M., Deaglio, Silvia, Gao, Wenda, Friedman, David, Strom, Terry B., Robson, Simon   +5 more
openaire   +6 more sources

Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy

Journal for ImmunoTherapy of Cancer, 2022
Background An important mechanism, by which cancer cells achieve immune escape, is the release of extracellular adenosine into their microenvironment. Adenosine activates adenosine A2A and A2B receptors on immune cells constituting one of the strongest ...
Julie Pelletier, Jean Sévigny, Laura Schäkel, Salahuddin Mirza, Riekje Winzer, Vittoria Lopez, Riham Idris, Haneen Al-Hroub, Eva Tolosa, Christa E Müller   +9 more
doaj   +1 more source

CD39/CD73/A2AR pathway and cancer immunotherapy

Molecular Cancer, 2023
AbstractCancer development is closely associated with immunosuppressive tumor microenvironment (TME) that attenuates antitumor immune responses and promotes tumor cell immunologic escape. The sequential conversion of extracellular ATP into adenosine by two important cell-surface ectonucleosidases CD39 and CD73 play critical roles in reshaping an ...
Chenglai Xia, Shuanghong Yin, Kenneth K. W. To, Liwu Fu   +3 more
openaire   +3 more sources